Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T‐cell lymphoma and cutaneous T‐cell lymphoma.

Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T-cell lymphoma and cutaneous T-cell lymphoma T-cell subpopulation analysis ( I n i = 6) showed mean CD4:CD8 ratio of 0.5 in trial patients prior to treatment compared to 1.5 for healthy age and sex-matched controls ( I p i = 0.016). The proportion of PD1+CD8+ effector T cells was lower in trial patients relative to healthy controls both before and after treatment ( I p i = 0.04 and 0.001, respectively). [Extracted from the article]